Armata Pharmaceuticals, Inc. (ARMP) Misses Q4 EPS by 323c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARMP Hot Sheet
Join SI Premium – FREE
Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q4 EPS of ($3.42), $3.23 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.48 million.
For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
- U.S. in talks with Venezuela for long-term military presence - NYT
- Madrigal Pharmaceuticals (MDGL) PT Raised to $760 at Citi
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
